Literature DB >> 2859021

Serum C-reactive protein in polymyalgia rheumatica. A prospective serial study.

R K Mallya, C R Hind, H Berry, M B Pepys.   

Abstract

A prospective serial study of 13 well-documented, previously untreated cases of polymyalgia rheumatica was undertaken in order to assess the behavior of the nonspecific indices of disease activity, erythrocyte sedimentation rate and serum C-reactive protein (CRP) concentration, during induction of disease remission by prednisolone therapy. The clinical manifestations of all patients responded rapidly and completely to steroids, and the serum CRP value, which was raised in all patients at presentation, fell to normal at a rate which precisely reflected the clinical improvement. The erythrocyte sedimentation rate also fell, but did so much more slowly than the CRP concentration and, in half the patients, was still not normal after 14 days. These results indicate that assay of serum CRP provides a precise means of objectively assessing the course of polymyalgia rheumatica during initial therapy with steroids, and suggest that routine measurements of CRP may make a useful contribution to the management of the disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859021     DOI: 10.1002/art.1780280405

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  Giant cell arteritis.

Authors:  V Kyle
Journal:  BMJ       Date:  1992-08-29

2.  Giant cell arteritis.

Authors:  J C Mason; M J Walport
Journal:  BMJ       Date:  1992-07-11

3.  Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis.

Authors:  D Caplanne; J M Le Parc; J A Alexandre
Journal:  Ann Rheum Dis       Date:  1996-06       Impact factor: 19.103

4.  Erythrocyte sedimentation rate and C reactive protein in the assessment of polymyalgia rheumatica/giant cell arteritis on presentation and during follow up.

Authors:  V Kyle; T E Cawston; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

Review 5.  Giant cell arteritis: difficult decisions in diagnosis, investigation and treatment.

Authors:  E W Paice
Journal:  Postgrad Med J       Date:  1989-10       Impact factor: 2.401

6.  CRP in the management of polymyalgia rheumatica and giant cell arteritis.

Authors:  S Schreiber
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

7.  Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica.

Authors:  T Ellingsen; P Elling; A Olson; H Elling; U Baandrup; K Matsushima; B Deleuran; K Stengaard-Pedersen
Journal:  Ann Rheum Dis       Date:  2000-10       Impact factor: 19.103

8.  The CRP initial response to treatment as prognostic factor in patients with polymyalgia rheumatica.

Authors:  S Schreiber; M Buyse
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980

9.  A new serological reaction in patients with polymyalgia rheumatica and/or giant cell (temporal) arteritis: deposition of complement C4 and C3 components on rat kidney structures detected by indirect immunofluorescence.

Authors:  P Vaith; D Maas; G von Stackelberg; H H Peter
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

10.  Plasma viscosity in giant cell arteritis as a predictor of disease activity.

Authors:  M Gudmundsson; E Nordborg; B A Bengtsson; A Bjelle
Journal:  Ann Rheum Dis       Date:  1993-02       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.